Update on Intra-Arterial Chemotherapy for Retinoblastoma
2014
Mario Zanaty | Guilherme Barros | Nohra Chalouhi | Robert M. Starke | Philip Manasseh | Stavropoula I. Tjoumakaris | Carol L. Shields | David Hasan | Ketan Bulsara | Robert H. Rosenwasser | Pascal Jabbour
The tools for managing retinoblastoma have been increasing in the past decade. While globe-salvage still relies heavily on intravenous chemotherapy, tumors in advanced stage that failed chemotherapy are now referred for intra-arterial chemotherapy (IAC) to avoid enucleation. However, IAC still has many obstacles to overcome. We present an update on the indications, complications, limitations, success, and technical aspects of IAC. Given its safety and high efficacy, it is expected that IAC will replace conventional strategies and will become a first-line option even for tumors that are amenable for other strategies.
Mostrar más [+] Menos [-]Información bibliográfica
Este registro bibliográfico ha sido proporcionado por Hindawi